Zachary M Sticher
Overview
Explore the profile of Zachary M Sticher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
404
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Welch S, Spengler J, Westover J, Bailey K, Davies K, Aida-Ficken V, et al.
Sci Transl Med
. 2024 Nov;
16(774):eado7034.
PMID: 39565871
Development of broad-spectrum antiviral therapies is critical for outbreak and pandemic preparedness against emerging and reemerging viruses. Viruses inducing hemorrhagic fevers cause high morbidity and mortality in humans and are...
2.
Lieber C, Kang H, Sobolik E, Sticher Z, Ngo V, Gewirtz A, et al.
J Virol
. 2024 Aug;
98(9):e0090524.
PMID: 39207133
Importance: Four years after the onset of the global coronavirus disease 2019 (COVID-19) pandemic, the immunocompromised are at greatest risk of developing life-threatening severe disease. However, specific treatment plans for...
3.
Lieber C, Kang H, Sobolik E, Sticher Z, Ngo V, Gewirtz A, et al.
bioRxiv
. 2024 Jun;
PMID: 38826222
Importance: Four years after the onset of the global COVID-19 pandemic, the immunocompromised are at greatest risk of developing life-threatening severe disease. However, specific treatment plans for this most vulnerable...
4.
Cox R, Wolf J, Lieberman N, Lieber C, Kang H, Sticher Z, et al.
Nat Commun
. 2024 Feb;
15(1):1189.
PMID: 38331906
Measles cases have surged pre-COVID-19 and the pandemic has aggravated the problem. Most measles-associated morbidity and mortality arises from destruction of pre-existing immune memory by measles virus (MeV), a paramyxovirus...
5.
Jacobs L, van der Westhuyzen A, Pribut N, Dentmon Z, Cui D, DErasmo M, et al.
ACS Med Chem Lett
. 2023 Oct;
14(10):1434-1440.
PMID: 37849558
The SARS-CoV-2 main protease (M) has been proven to be a highly effective target for therapeutic intervention, yet only one drug currently holds FDA approval status for this target. We...
6.
Cox R, Lieber C, Wolf J, Karimi A, Lieberman N, Sticher Z, et al.
Nat Commun
. 2023 Aug;
14(1):4731.
PMID: 37550333
Therapeutic options against SARS-CoV-2 are underutilized. Two oral drugs, molnupiravir and paxlovid (nirmatrelvir/ritonavir), have received emergency use authorization. Initial trials suggested greater efficacy of paxlovid, but recent studies indicated comparable...
7.
Lieber C, Aggarwal M, Yoon J, Cox R, Kang H, Sourimant J, et al.
PLoS Pathog
. 2023 Apr;
19(4):e1011342.
PMID: 37068076
Influenza outbreaks are associated with substantial morbidity, mortality and economic burden. Next generation antivirals are needed to treat seasonal infections and prepare against zoonotic spillover of avian influenza viruses with...
8.
Cox R, Lieber C, Wolf J, Karimi A, Lieberman N, Sticher Z, et al.
bioRxiv
. 2022 Dec;
PMID: 36451893
Despite the continued spread of SARS-CoV-2 and emergence of variants of concern (VOC) that are capable of escaping preexisting immunity, therapeutic options are underutilized. In addition to preventing severe disease...
9.
Lieber C, Cox R, Sourimant J, Wolf J, Juergens K, Phung Q, et al.
Nat Commun
. 2022 Jul;
13(1):4416.
PMID: 35906230
SARS-CoV-2 variants of concern (VOC) have triggered infection waves. Oral antivirals such as molnupiravir promise to improve disease management, but efficacy against VOC delta was questioned and potency against omicron...
10.
Wittwer K, Anderson D, Pfeffermann K, Cox R, Wolf J, Santibanez S, et al.
Nat Commun
. 2021 Sep;
12(1):5233.
PMID: 34475387
Measles virus (MeV) is a highly contagious pathogen that enters the human host via the respiratory route. Besides acute pathologies including fever, cough and the characteristic measles rash, the infection...